131 studies found for:    daniel lee | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Cochlear Implantation for Treatment of Single-sided Deafness
Conditions: Total Unilateral Deafness;   Unilateral Partial Deafness
Intervention: Device: Med-el MAESTRO Cochlear Implant with Flex 28 electrode array
2 Recruiting Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects
Condition: Bilateral Hearing Loss for Causes Other Than Tumors
Intervention: Device: Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
3 Recruiting Absorb IV Randomized Controlled Trial
Conditions: Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions: Device: Absorb BVS;   Device: XIENCE
4 Recruiting Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Conditions: Diabetic Retinopathy;   HIV
Interventions: Drug: Tesamorelin;   Drug: Placebo-Control
5 Recruiting Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects
Condition: Bilateral Hearing Loss for Causes Other Than Tumors
Intervention: Device: Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
6 Recruiting Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms
Condition: Breast Implant
Intervention:
7 Unknown  Vitamin E Supplementation in Burn Patients
Condition: Burn Injury
Intervention: Dietary Supplement: dl-alpha-tocopheryl acetate
8 Available Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Conditions: Neurofibromatosis Type 2;   Severe Profound Sensorineural Hearing Loss
Intervention: Device: Nucleus Profile ABI541 Auditory Brainstem Implant
9 Recruiting S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
10 Recruiting A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
Condition: Chronic Myeloid Leukemia
Interventions: Drug: 600mg/day of Imatinib;   Drug: 400mg/day of Imatinib
11 Recruiting Selinexor (KPT-330) in Older Patients With Relapsed AML
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Selinexor;   Drug: Hydroxyurea;   Drug: Ara-C;   Drug: azacitidine;   Drug: Decitabine
12 Recruiting S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo
13 Recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Conditions: Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IB Squamous Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIA Squamous Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIB Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Squamous Cell Lung Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
14 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
15 Recruiting ExploR™ Modular Radial Head Data Collection
Condition: Elbow Fracture
Intervention: Device: Explore Modular Radial Head
16 Recruiting Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
Condition: Benign Prostatic Hyperplasia (BPH)
Interventions: Device: Aquablation;   Procedure: Transurethral Resection of the Prostate (TURP)
17 Recruiting Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
Condition: Mesothelioma
Intervention:
18 Recruiting Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Biological: Rilotumumab;   Drug: Taselisib
19 Recruiting S0820, Adenoma and Second Primary Prevention Trial
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
20 Recruiting Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: abiraterone;   Drug: prednisone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years